RYBODYN ANNOUNCES SEED FINANCING TO ADVANCE AI-DRIVEN DISCOVERY OF HIDDEN CANCER TARGETS
RyboDyn, Inc., a biotechnology company decoding the dark proteome using an AI-powered novel sequencing and discovery platform, today announced the initial close of a $10M Seed financing from a syndicate of new and existing investors. The financing will accelerate the company's transition from foundational discovery into scaled platform execution and progress early-stage programs into IND-enabling studies.
THE BOTTLENECK IS TARGET DISCOVERY
Oncology drug development is facing a paradox. While advances in AI and protein engineering are frequently touted as significantly accelerating drug design, the targets those drugs chase are more crowded than ever. The well-known EGFR target has over 200 drugs approved or in development, and the PD-1/PD-L1 checkpoint axis has nearly 200 more. In an era of intense focus on AI-driven drug design, the bottleneck is no longer the ability to design high-affinity molecules — its target discovery. The field needs new biology, and conventional genomics has largely run out of it.
RyboDyn is looking somewhere else entirely.
For decades, much of the human genome — nearly 98% — was considered "junk" DNA. We now know that some of these regions are transcriptionally active, yet they remain largely invisible to conventional sequencing approaches. RyboDyn has built the tools to decipher this hidden code to reveal novel biology, and is now translating these discoveries into actionable cancer targets to enable first-in-class therapies for patients with limited or no treatment options.
THE PLATFORM: RYBOCYPHER™ & CYPHERATLAS™
At the core is RyboCypher™, the company's proprietary discovery engine, which combines deep sequencing of non-canonical RNAs with proteomic detection to identify disease-specific, druggable targets directly from patient tumors. These data are continuously integrated into CypherAtlas™, creating a proprietary, searchable atlas that powers foundational AI models to decode the dark proteome at scale.
Since announcing the discovery of a cryptic human proteome last year — initially demonstrated as proof-of-concept in cell line models — RyboDyn has rapidly expanded CypherAtlas™ to include data from approximately 1,000 patient tumor samples across 10 distinct oncology indications. Key milestones include:
Discovery of more than 3 million conserved, novel dark RNAs (previously uncharacterized)
More than a 100-fold increase in the number of cryptic peptides encoded by these dark RNA species
Over 80,000 cryptic peptides identified empirically by mass spectrometry, including ~15,000 cancer-specific peptides
Many of these proteins contain recognizable functional domains, suggesting roles as cryptic transcription factors, regulatory proteins, and novel cancer drivers. They are frequently localized to the cell surface or secreted into the extracellular space — making them especially attractive therapeutic targets. Membrane-bound and focal adhesion-associated proteins are emerging as high-priority opportunities for targeted immunotherapies.
CypherAtlas™ is now the largest integrated dark transcriptome and proteome resource in the field.
"We set out to find the proteins that cancer hides behind, and we're now uncovering them at scale. RyboCypher™ and CypherAtlas™ provide a continuously expanding map of that hidden biology. We're actively translating these discoveries into first-in-class therapies, both internally and with leading pharmaceutical partners."
— Imad Ajjawi, PhD, MBA, CEO and Co-founder, RyboDyn
AN UNCONTESTED TARGET LANDSCAPE
RyboDyn's novel cryptic targets represent an entirely uncontested target landscape. While established oncology targets each have hundreds of drugs in development, those therapies are inherently limited to patients who express those targets. HER2, for example, is present in only ~15–20% of breast cancer patients, leaving the majority without access to viable targeted immunotherapies.
RyboDyn's cryptic targets expand beyond conventional target space, enabling novel, tumor-specific therapies for broader patient populations.
"It's clear that the molecules we're finding and describing for the first time represent a vast opportunity to tackle some of the most aggressive cancers. In a cohort of HER2-negative breast cancer patients, we identified a novel target present in approximately 45% of the tumors we analyzed — some of these are triple-negative patients with limited treatment options. That's the value proposition of our approach; the integration of RyboCypher™ with CypherAtlas™ allows us to identify entirely new, actionable targets."
— Dr. Corey Dambacher, President and Co-founder, RyboDyn
PROOF-OF-CONCEPT & INVESTOR CONFIDENCE
The company has already demonstrated proof-of-concept in vitro, including the first-ever ADC-mediated killing of tumor cells via a cryptic protein target — a milestone that helped catalyze the current financing.
"RyboDyn is tackling one of the most underexplored frontiers in cancer biology. Their ability to systematically discover and validate targets from the dark proteome at this scale is highly differentiated. This new therapeutic landscape represents a fundamental shift in how cancer is targeted, and RyboDyn is pioneering this shift."
— Eric Woersching, Managing Partner, Massive Tech Ventures
Read the full press release: https://www.prnewswire.com/news-releases/rybodyn-announces-seed-financing-to-advance-ai-driven-discovery-of-hidden-cancer-targets-302722950.html